We are excited to share some news of great scientific and clinical relevance. Ionis Pharmaceuticals has announced the completion of a licensing agreement for ION283, their investigational drug for the treatment of Lafora disease.
News
Riconoscimento di un Traguardo Storico
Riconoscimento di un Traguardo Storico nella Ricerca sulla Malattia di Lafora Con immensa gioia e profonda gratitudine, ci accingiamo ad annunciare un traguardo atteso per anni, segnato da un’ardente[...]
Read moreFIRST GOAL ACHIEVED!
We have reached our first goal. Thanks to the many donations received, Tempo Zero has raised the first 50,000 euros, which will allow us to launch a specific research grant for Lafora disease in the s[...]
Read more